Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is a leading healthcare supply chain company with a competitive advantage in the US market, backed by a strong customer base and strategic partnerships with major health systems. With investments in technology and an extensive product portfolio, the company is well-positioned for continued growth and profitability. From a financial standpoint, Medline's 2025 IPO and planned technology-driven strategies show potential for a favorable return for investors within the next 12 months.

Bears say

Medline is poised for strong growth as it leverages its scale, technology-enabled solutions, and broad product offerings to meet the increasing demand for healthcare products. However, near-term challenges such as fire-related inefficiencies, tariffs, and elevated freight costs may moderate profitability. Additionally, the stock's current valuation, based on an equity value multiple of 12 times projected EBITDAR and 18 times projected NOPAT, leaves little room for upside potential.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.